(Q45412652)

English

P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma.

scientific article published in October 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Ju-Bo Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Wei-Zhong Wu

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Hong-Bin Fang

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Wei-Dong Jia

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Peng-Yuan Zhuang

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Bo-Heng Zhang

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Qi Pan

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Yang Xu

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Lu Wang

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Zhao-You Tang

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Hui-Chuan Sun

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

language of work or name

0 references

publication date

1 October 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

107

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1562-1569

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16948122%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Preventive treatments for recurrence after curative resection of hepatocellular carcinoma--a literature review of randomized control trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

21 January 2018

Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

21 January 2018

Global cancer statistics in the year 2000.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimates of the worldwide incidence of 25 major cancers in 1990.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction in p48-ISGFgamma levels confers resistance to interferon-alpha2a in MHCC97 cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

The janus kinase inhibitor, Jab/SOCS-1, is an interferon-gamma inducible gene and determines the sensitivity to interferons

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

The interferon-inducible Stat2:Stat1 heterodimer preferentially binds in vitro to a consensus element found in the promoters of a subset of interferon-stimulated genes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

p48 Overexpression enhances interferon-mediated expression and activity of double-stranded RNA-dependent protein kinase in human hepatoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22206

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45412652&oldid=1424754927"